Pharmacokinetics of CPU0213, a novel endothelin receptor antagonist, after intravenous administration in mice1
Open Access
- 1 March 2006
- journal article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 27 (3) , 367-371
- https://doi.org/10.1111/j.1745-7254.2006.00288.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Regression of Renal Vascular Fibrosis by Endothelin Receptor AntagonismHypertension, 2001
- Endothelins and Endothelin Receptor AntagonistsCirculation, 2000
- Endothelin-receptor antagonists: current and future perspectivesDrug Discovery Today, 2000
- Role of Endothelin-1 in HypertensionHypertension, 1999
- Heart failure and endothelin receptor antagonistsTrends in Pharmacological Sciences, 1999
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988
- Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolusClinical Pharmacology & Therapeutics, 1987
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974
- THE CALCULATION OF THE DOSAGE‐MORTALITY CURVEAnnals of Applied Biology, 1935